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Abstract
Background: Urinary steroid profiling (USP) is a powerful 
diagnostic tool to asses disorders of steroidogenesis. Pre-
analytical factors such as age, sex and use of oral contra-
ceptive pills (OCP) may affect steroid hormone synthesis 
and metabolism. In general, USP reference intervals are 
not adjusted for these variables. In this study we aimed to 
establish such reference intervals using a newly- developed 
and validated gas chromatography with tandem mass 
spectrometry detection method (GC-MS/MS).
Methods: Two hundred and forty healthy subjects aged 
20–79 years, stratified into six consecutive decade groups 
each containing 20 males and 20 females, were included. 
None of the subjects used medications. In addition, 
40 women aged 20–39 years using OCP were selected. A 
GC-MS/MS assay, using hydrolysis, solid phase extraction 
and double derivatization, was extensively validated and 
applied for determining USP reference intervals.
Results: Androgen metabolite excretion declined with age 
in both men and women. Cortisol metabolite excretion 
remained constant during life in both sexes but increased 
in women 70–79  years of age. Progesterone metabolite 
excretion peaked in 30–39-year-old women and declined 
afterwards. Women using OCP had lower excretions of 
androgen metabolites, progesterone metabolites and 
cortisol metabolites. Method validation results met 
prerequisites and revealed the robustness of the GC-MS/
MS method.
Conclusions: We developed a new GC-MS/MS method for 
USP which is applicable for high throughput analysis. 
Widely applicable age and sex specific reference intervals 
for 33  metabolites and their diagnostic ratios have been 
defined. In addition to age and gender, USP reference 
intervals should be adjusted for OCP use.
Keywords: GC-MS/MS; oral contraceptive pills; reference 
intervals; urinary steroid profile.
Introduction
Steroid biosynthesis is a complex process by which 
steroid hormones are produced from cholesterol through 
a series of unique enzymatic steps in steroidogenic tissue 
[1]. This tissue is mainly found in the adrenal cortex and 
gonads [2]. Steroid hormones can be classified according 
to their physiological function into progestins, androgens, 
estrogens, mineralocorticoids and glucocorticoids. As 
such, they regulate various biological processes includ-
ing mineral balance, intermediate metabolism, sexual 
development, reproductive function, immune and stress 
responses [3]. Steroids are converted into a large number 
of metabolites by the liver and peripheral tissues before 
being excreted in the urine. The biochemistry of steroid 
biosynthesis and metabolism is largely known and spe-
cific steroid pathways are regulated by differential expres-
sion and activity of enzymes and cofactors involved in a 
developmental, sex, time and tissue specific fashion and 
might be perturbed in disease states [4].
Since the 1960s, urinary steroid profiling (USP) has 
been a powerful diagnostic tool to assess steroidogenesis. 
Nowadays, USP is usually being performed by application 
of gas chromatography-mass spectrometry (GC-MS) [4, 5]. 
This technique is able to measure a wide variety of urinary 
steroid hormone metabolites at the same time in one 
urinary sample, making it an efficient and patient friendly 
diagnostic tool. For the last 50 years almost all disorders 
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of steroid hormone biosynthesis and metabolism have 
been characterized and first named following urinary 
steroid analysis [4].
USP has a broad range of applications. For example, 
it can be used for the diagnosis and follow-up of disorders 
resulting from steroid biosynthetic enzyme deficiencies, 
licorice-induced hypertension, hirsutism and other related 
diseases [6–8]. Furthermore, USP might be helpful in mon-
itoring patients with an adrenocortical carcinoma (ACC) 
and could be useful in discriminating between malignant 
and benign adrenal tumors [9–12]. Reference intervals for 
USP using GC-MS have been described before [6, 11, 13–17]. 
Notably, those previous studies have several shortcom-
ings, such as lack of adjustment for potential relevant pre- 
analytical factors like age, sex or use of oral contraceptive 
pills (OCP) or limited external validity as a result of the 
examination of study subjects who may not accurately 
reflect the general population. Reliable reference intervals 
for urinary steroid metabolites are a prerequisite for correct 
interpretation of USP test results in clinical practice.
In this study we aim to establish age- and sex-specific 
USP reference intervals in a well-defined healthy adult 
population. In addition, USP reference intervals were 
determined in a subgroup of women using OCP. USP was 
performed by using a newly developed gas chromato-
graphy-tandem mass spectrometry (GC-MS/MS) assay. In 
comparison with other USP methods such as GC-MS, it 
has been suggested that GC-MS/MS demonstrates higher 




Two hundred and eighty healthy subjects with a body mass index 
between 21 and 30 kg/m2 and age between 20 and 79  years were 
selected from the Life Lines Cohort Study, a large population-
based cohort study in the Netherlands [18]. Of these, 240  subjects 
were stratified into six consecutive decade groups, each containing 
20 males and 20 females. None of the subjects used any medication. 
In the subgroup of women between 20 and 39 years who were not 
using OCPs, any women using OCP were excluded.
In addition, 40 women aged 20–39 years (20 subjects per dec-
ade), using OCP were selected. Women on OCP used combined con-
traceptives with different progestogens, but mostly levonogestrel 
combined with ethinylestradiol. Urinary samples from 24  h collec-
tions had been stored at −80 °C until analysis. In women, urinary 
collections were not timed according to menstrual cycle or day of 
OCP use. The study was approved by the Medical Ethics Committee 
of the University of Groningen and all participants provided written 
informed consent.
Reagents and stock solutions
Methoxyamine HCl, trimethylsilylimidazole (TMSI) and sodium 
ascorbate were purchased from Sigma Aldrich Corp. (St. Louis, MO, 
USA). Pyridine was obtained from Merck (Kenilworth, NJ, USA), hep-
tane and methanol from Biosolve BV (Valkenswaard, The Nether-
lands), and Suc d’Helix from Brunschwig Chemie (Amsterdam, The 
Netherlands).
Androsterone (A), etiocholanolone (E), dehydroepiandrosterone 
(DHEA), 11-keto-etiocholanolone (11-KE), 11-hydroxyandrosterone (11-
HA), 11-hydroxyetiocholanolone (11-HE), epipregnanolone (polone), 
16-α hydroxydehydroepiandrosterone (16-OH-DHEA), allo-pregnane-
diol (aP2), pregnanediol (P2), pregnanetriol (P3), 16-ketoandrosten-
ediol (16-KA’2), androstenetriol (A’3), tetrahydrodeoxycortisol (THS), 
11-deoxytetrahydrocorticosterone (TH-DOC), pregnanetriolone (PTL), 
16-α hydroxypregnenolone (16-OH-P’OL), 17-hydroxypregnenetriol 
(17-P3), tetrahydrocortison (THE), 11-dehydrotetrahydrocorticoster-
one (THA), tetrahydrocorticosterone (THB), allo-tetrahydrocorti-
costerone (aTHB), tetrahydrocortisol (THF), allo-tetrahydrocortisol 
(aTHF), α cortolone (α-CTLN), β cortolone (β-CTLN), pregnanedi-
olone (PDL) and allo-pregnanediolone (aPDL) were all obtained from 
Steraloids (Newport, RI, USA). Estriol and α-cortol (α-cortol) were 
from Sigma Aldrich Corp. (St. Louis, MO, USA). See Supplementary 
Table 1 for steroid nomenclature according to IUPAC, LOINC and 
Chemspider.
Isotope-labeled internal standards 11-KE-d5, pregnenolone-
d4 and THE-d5 were purchased from CDN isotopes; DHEA-d6 from 
Sigma Aldrich Corp. (St. Louis, MO, USA). We used four deuterated 
internal standards divided over the 33 steroid metabolites represent-
ing polarity groups, because of availability and costs.
For 3α, 15β, 17α-trihydroxypregnanediolone (15-OH-PDL), 
15-hydroxypregnenolone (15-OH-P’DL) and 16-β,18-dihydroxy-
dehydroepiandrosterone (16,18-OH2-DHEA) we have no standards 
available.
Stock solutions were prepared in methanol and serially diluted 
to form calibrators and quality control samples in urine by enrich-
ment. The exact concentration range of calibrators varies with the 
analyte, for example, 0–27 µmol/L for THF and 0–36 µmol/L for E. 
Internal standards concentrations were 6 µmol/L.
Instrumentation
Solid phase extraction (SPE) was performed on Waters Oasis HLB 
(3 mL Vac cartridges, 60  mg sorbent per cartridge, 30 µm parti-
cle size (Waters Corporation, Milford, MA, USA). Steroids were 
chromatographically separated on a J&W CP-Sil 5 CB column 
(25 m × 250 µm × 0.12 µm; Agilent Technologies, Santa Clara, CA, 
USA). A 7890A GC with 7000 Triple Quadrupole Detector (Agilent 
Technologies, Santa Clara, CA, USA) was used for separation and 
detection using electron impact and selective reaction monitor-
ing. Nitrogen was used as collision gas (flow 1.5 mL/min), helium 
as quench gas (flow 2.25 mL/min) and carrier gas (2 mL/min). The 
injection temperature was 65 °C, with the MS source at 270 °C 
and both quadrupoles at 150 °C. Chromatography was performed 
using a temperature program for optimal separation: 2 min 50 °C, 
ramp 40 °C/min until 160 °C, ramp 2.5 °C/min until 240 °C and 
finally ramp 4 °C/min until 270 °C. Electron impact was performed 
at 70 eV.
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Data acquisition was performed with Masshunter Version B 
06.01 (Agilent Technologies, Santa Clara, CA, USA) and data were 
processed with Masshunter Quantitative Analysis Version B07.00/
Build 7.0.457.0 (for QQQ).
Analytical principle
Glucuronide- and sulfate-conjugated steroid hormone metabo-
lites were measured in samples from 24 h urine collections. First, 
conjugated hormones were converted to the free steroid form by 
enzymatic hydrolysis. Isotope-labeled internal standards 11-KE-d5, 
DHEA-d6, pregnenolone-d4 and THE-d5 were added and unconju-
gated steroids were extracted from urine by using SPE. Polar com-
ponents were washed out of the extract. The extract was vaporized 
using an infrared vaporizer, after which the residue was derivatized 
at hydroxyl- and keto-residues, in a two-step reaction to decrease 
polarity. Keto-residues were derivatized using 2% methoxyamine 
in pyridine; hydroxyl-residues were silylated by N-trimethylsilyl 
imidazole.
Sample preparation
Before analysis, urinary samples were centrifuged at 1200 g before 
applying 1 mL to conditioned (methanol, water) HLB SPE columns. 
Cartridges were washed with water and eluted with methanol. The 
eluate was vaporized using an infrared vaporizer (Hettlab IR Dancer 
300, Hettich AG, Switzerland) and rediluted in 2 mL acetate/sodium 
ascorbate (pH 4, 8) solution. One hundred microliters Suc d’Helix 
Pomatia was added and enzymatic hydrolysis of the conjugated 
groups took place during 2 h at 46 °C in a shaking temperature con-
trolled bath. After cooling down, internal standards were added and 
a second SPE step took place on the HLB columns. Samples were 
washed with water, eluted with methanol and evaporated until 
dryness. The residue was derivatized with 150 µL methoxyamine in 
pyridine during 1 h at 80 °C. After evaporation until dryness a second 
derivatization step took place with 200 µL N-trimethylsilyl imidazole 
during 12 h (overnight) at 110 °C. In case of emergency diagnostics 
this last step can be reduced to 2 h at 140 °C.
Samples were washed with 4 mL heptane and 3 mL 0.1 M HCl 
by vortexing and centrifugation (1200 g). One milliliters of the upper 
heptane layer were transferred to a GC-MS/MS vial. Injection volume 
was 25 µL.
Analytical method validation
Prior to validation, claims were postulated for each validation 
parameter, according to the international ISO15189 regulation and 
the Dutch guideline for validation of analytical methods in medical 
laboratories by the Dutch Society of Clinical Chemistry and Labo-
ratory Medicine (NVKC) [19]. Validation parameters applied were 
intra-assay (n = 20) and inter-assay (n = 16) imprecision, repeat-
ability of the injection (n = 10), linearity (n = 6), recovery (n = 6 for 
three concentrations), lower limit of quantitation (LLOQ), minimal 
sample volume, carry-over, method comparison against the previ-
ous GC-MS method using liquid-liquid extraction and overnight 
hydrolysis at 37 °C using a buffer without sodium ascorbate [7] and 
stability of six different urinary samples (biological sample, freeze-
thaw, autosampler).
Statistical analysis
GC-MS/MS and GC-MS methods were compared using Passing-
Bablok regression analysis in Analyse-it (version 2.30 Excel 12+ Ana-
lyse-it Software). USP results from healthy volunteers were analyzed 
to obtain age, sex and OCP specific reference intervals for 33 steroid 
metabolites. Also diagnostic steroid ratio reference intervals were 
Figure 1: Total ion current chromatogram of a calibration standard  mix of all the steroid metabolites.
A, androsterone; E, etiocholanolone; DHEA, dehydroepiandrosterone; 11-KE, 11-keto-etiocholanolone; 11-HA, 11-hydroxyandrosterone; 11-HE, 
11-hydroxyetiocholanolone; polone, epipregnanolone; 16-OH-DHEA, 16-α hydroxydehydroepiandrosterone; aP2, allo-pregnanediol; P2, preg-
nanediol; P3, pregnanetriol; 16-KA’2, 16-ketoandrostenediol; A’3, androstenetriol; THS, tetrahydrodeoxycortisol; TH-DOC, 11-deoxytetrahydro-
corticosterone; PTL, pregnanetriolone; 16-OH-P’OL, 16-α hydroxypregnenolone; 17-P3, 17-hydroxypregnenetriol; THE, tetrahydrocortison; THA, 
11-dehydrotetrahydrocorticosterone; THB, tetrahydrocorticosterone; aTHB, allo-tetrahydrocorticosterone; THF, tetrahydrocortisol; aTHF, allo-
tetrahydrocortisol; α-CTLN, α cortolone; β-CTLN, β cortolone; PDL, pregnanediolone; aPDL, allo-pregnanediolone; α-cortol, α-cortol. Standards 
for 3α, 15β, 17α-trihydroxypregnanediolone (15-OH-PDL), 15-hydroxypregnenolone (15-OH-P’DL) and 16-β,18-dihydroxy-dehydroepiandrosterone 
(16,18-OH2-DHEA) were not available. See Supplementary Table 1 for steroid nomenclature according to IUPAC, LOINC and Chemspider.
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Table 1: Mass spectrometric settings for steroid metabolites and internal standards.
Steroid metabolite   Precursor ion, m/z   Product ion, m/z   Collision energy, V   Dwell time, ms  Internal standard
[D5] 11-KE   305.1   258.2   10   50 
[D6] DHEA   364.2   274   3   50 
[D5] THE   583.3   403.2   12   50 
[D4] Pregnenolone   390.2   300.1   7   30 
11-HA   448.2   358.2   3   20  D6-DHEA
11-HE   448.2   268.2   10   40  D6-DHEA
11-KE   300.1   254.2   10   50  D5-11-KE
15-OH-PDL   258   168.1   8   40  D5-THE
15-OH-P’DL   562   472.3   8   30  D5-THE
16,18-OH2-DHEA   534   444   10   30  D5-11-KE
16K-A’2   446.2   356.2   7   40  D6-DHEA
16-OH-DHEA   266   239.1   10   40  D5-11-KE
16-OH-p’ol   474.3   156   18   10  D5-11-KE
17-P3   433.2   253.3   7   10  D5-THE
A   360.2   270.2   5   50  D4-Pregnenolone
A’3   329   239.1   15   30  D5-THE
aP2   269.2   187   3   30  D5-THE
aPDL   476.3   386.3   10   40  D5-THE
aTHB   474   384.3   5   100  D5-THE
aTHF   472   382.1   15   80  D5-THE
α-cortol   343.3   199   5   30  D5-THE
α-CTLN   449.2   359.3   5   30  D5-THE
β-CTLN   449.2   359.3   3   30  D5-THE
DHEA   358.2   268   3   50  D6-DHEA
E   360.2   270.2   5   50  D4-Pregnenolone
Oestriol   504.3   414.1   3   40  D5-THE
P2   269.2   187   3   30  D5-THE
P3   435.3   255.2   5   20  D5-THE
PDL   476.3   386.3   10   40  D5-THE
Polone   388.2   298.2   10   40  D4-Pregnenolone
PTL   449.2   359.3   3   30  D5-THE
THA   400   241   5   30  D5-THE
THB   474   384.3   5   100  D5-THE
TH-DOC   476.3   241.2   10   30  D5-THE
THE   578.3   398.2   12   50  D5-THE
THF   472   382.1   15   80  D5-THE
THS   564.3   474.2   12   40  D5-THE
Abbreviations as in Figure 1 and Supplemental Table 1.
calculated from these data. Reference intervals were defined as the 
central 95% of the population (i.e. the 2.5th and 97.5th percentiles) 
and calculated using EP evaluator. Non-parametric data were loga-
rithmically transformed before analysis.
Differences in the distributions of urinary steroid metabo-
litesin relation to OCP use were assessed using the Kolmogorov-
Smirnov test. Metabolites were categorized in androgen (A, E, 
DHEA, 11-KE, 11-HA, 11-HE), cortisol (THE, THF, aTHF, α-CTLN, 
β-CTLN, α-cortol), progesterone (aP2, P2, P3, Polone), aldosterone 
(THA, THB, aTHB), intermediate (THS, PDL, PTL, aPDL, TH-DOC) 
and fetal (A’3, 16K-A’2, 16-OH-DHEA, 16,18-(OH)2-DHEA, 16-OH-p’ol, 
15-OH-PDL, 17-P3, 15-OH-P’DL) metabolites. Sum scores were cal-
culated per group and differences between groups were calculated 
using the Mann-Whitney test. Additional statistical analyses were 
performed using SPSS version 23.0 for Windows (IBM Corporation, 




In one chromatographic run, we quantified 33 urinary 
steroid metabolites, as shown in the total ion current 
chromatogram (Figure 1) and mass spectrometric settings 
(Table 1). Calibration curves (weighed regression) and 
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validation samples were run with every batch of patient 
samples. Linearity was obtained over the 0–35 µmol/L 
range with corresponding correlation coefficients (R2) 
consistently >0.99 for all steroids. Calibration curves were 
also reproducible between days (n = 6) with R2 > 0.95. Coef-
ficient of variation (CVs) of slopes between days were <3% 
(calibration data not shown).
Intra-assay imprecision (n = 20), inter-assay impreci-
sion (n = 16) and repeatability imprecision (n = 10) were 
<10% except for 16-KA’2, which showed an intra- and 
inter-assay imprecision of 14% and 16%, respectively 
(data not shown). Recoveries (n = 6) measured by spiking 
urine samples with three different concentrations of 
standard solution, ranged from 89% to 112%, as shown in 
 Supplementary Table 2.
The LLOQ, or functional sensitivity, was at least 
0.1 µmol/L for each analyte with a CV < 20% (data not 
shown). The minimal sample volume was established to 
be 500 µL.
The method did not suffer from carry-over (<0.1% for 
all analytes, data not shown).
Primary urine samples were stable at room tempera-
ture for at least 1 week, at 4 °C for at least 8 weeks and 
at –20 °C for at least 12  weeks. Samples were stable for 
at least 4 freeze-thaw cycles. Derivatized samples were 
stable for at least 2 weeks in the autosampler (room tem-
perature). Stability data are shown in Table 2.
Method comparison
We compared the results obtained by the newly- developed 
GC-MS/MS and the former GC-MS method in a series of 
patients specimens routinely analyzed for USP at our labo-
ratory. Passing-Bablok regression (n = 20) showed slightly 
lower concentrations for A, 11-KE, PDL, 11-HA, 11-HE, 
aPDL, aP2, P2, P3, A’3, PTL, 17-P’3, THA, THB, aTHB, THF, 
aTHF and α-cortol when quantified with the new GC-MS/
Table 2: Stability of steroid metabolites (n = 6).
Steroid metabolite   Room temperature, days  4 °C, days   −20 °C, days   Freeze/thaw, cycles   Autosampler, days
A   >90   >90   >90   4   >14
E   83   >90   >90   4   >14
DHEA   25   >90   >90   4   >14
11-KE   24   >90   >90   4   >14
PDL   41   >90   >90   4   >14
11-HA   >90   >90   >90   4   >14
11-HE   >90   >90   >90   4   >14
Polone   Not tested   Not tested   Not tested   Not tested   >14
aPDL   Not tested   Not tested   Not tested   Not tested   >14
16-OH-DHEA   6   55   >90   4   >14
aP2   >90   >90   >90   4   >14
P2   >90   >90   >90   4   >14
P3   46   >90   >90   4   >14
16-KA’2   Not tested   Not tested   Not tested   Not tested   >14
A3   11   >90   >90   4   >14
THS   19   >90   >90   4   >14
Oestriol   Not tested   Not tested   Not tested   Not tested   >14
TH-DOC   Not tested   Not tested   Not tested   Not tested   >14
PTL   >90   >90   >90   4   >14
16-OH-p’ol   Not tested   Not tested   Not tested   Not tested   >14
17-P3   12   >90   >90   4   >14
THE   23   >90   >90   4   >14
THA   33   >90   >90   4   >14
THB   >90   >90   >90   4   >14
aTHB   >90   >90   >90   4   >14
THF   >90   >90   >90   4   >14
aTHF   >90   >90   >90   4   >14
α-CTLN   29   65   >90   4   >14
β-CTLN   37   55   >90   4   >14
α-cortol   >90   >90   >90   4   >14
Abbreviations as in Figure 1 and Supplemental Table 1.
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MS method compared to the GC-MS method, as shown in 
Supplementary Table 3.
Reference intervals and influence of OCP
As shown in Tables 3 and 4, almost all steroid excretions 
were different between the various age and sex groups. 
Androgen metabolite excretion declined with age in men 
and women, with absolute concentrations much higher 
in men compared to women (Figures 2 and 3). Cortisol 
metabolite excretion remained constant during life in 
both sexes but increased in women 70–79  years of age. 
Progesterone metabolite excretion peaked in 30–39 year 
old women and declined afterwards. Fetal metabolites 
declined in both sexes during life. In addition to absolute 


















  Meana Reference 
interval
  Meana Reference 
interval
  Meana Reference 
interval
  Meana Reference 
interval




 A   6.8–36.4   21.6   6.4–29.0   13.7(NP)   5.5–22.7   14.0   3.2–17.6   10.4   3.5–14.7   6.8(NP)   2.6–11.0   6.8
 E   5.0–39.9   13.5(NP)   0.3–16.9   8.6   3.1–16.1   9.6   1.2–16.1   8.6   1.5–13.0   7.3   2.1–12.1   7.0
 DHEA   0.5–41.2   6.6(NP)   0.2–17.3   1.5(NP)   0.6–12.9   2.6(NP)   0.2–7.0   1.1(NP)   0.2–3.2   0.6(NP)   0.1–7.8   0.9(NP)
 11-KE   0.1–3.6   1.8   0.1–3.5   1.6   0.1–3.4   1.7   0.4–5.2   1.8(NP)   0.5–4.8   1.9(NP)   0.4–4.6   1.7(NP)
 11-HA   1.1–9.5   5.3   1.1–6.9   4.0   2.3–7.2   4.8   2.2–8.1   4.2(NP)   0.9–8.2   4.5   1.6–7.3   4.4
 11-HE   0.1–4.0   1.9   0.0–4.7   1.6(NP)   0.1–4.1   1.9   0.1–4.6   2.0   0.2–6.3   1.4(NP)   0.5–7.6   1.9(NP)
 Estriol   <0.1   <0.1   <0.1   <0.1   <0.1   <0.1   <0.1   <0.1   <0.1   <0.1   <0.1   <0.1
Cortisol
 THE   5.0–25.3   15.2   6.5–24.7   12.9(NP)   7.1–20.9   14.0   5.1–24.2   14.7   5.4–23.0   14.2   5.6–22.6   14.1
 THF   3.5–13.5   6.9(NP)   3.1–10.0   6.5   3.8–10.6   7.2   2.5–13.4   7.9   3.9–16.0   8.2(NP)   4.0–15.3   9.7
 aTHF   2.5–21.6   7.4(NP)   1.8–15.3   8.5   3.9–12.8   8.3   3.3–14.7   7.1(NP)   3.0–13.2   5.9(NP)   1.6–12.4   7.0
 α-CTLN   2.2–8.5   5.4   2.7–6.7   4.3(NP)   2.8–6.7   4.8   1.9–7.3   4.6   1.5–8.6   5.0   2.1–8.3   5.2
 β-CTLN   1.4–6.1   2.7(NP)   0.9–4.5   2.7   1.0–4.5   2.7   0.9–4.5   2.7   1.3–4.8   2.5(NP)   0.9–4.1   2.5
 α-cortol   0.5–1.7   0.8(NP)   0.5–1.2   0.7(NP)   0.5–1.2   0.9   0.4–1.6   0.8(NP)   0.2–1.8   1.0   0.3–2.1   1.2
Progesterone 
 aP2   0.2–1.3   0.4(NP)   0.1–0.9   0.4(NP)   0.1–0.7   0.4   0.0–0.6   0.3   0.0–0.6   0.2(NP)   0.0–0.5   0.2(NP)
 P2   0.6–3.7   1.3(NP)   0.3–2.4   1.0(NP)   0.5–2.2   1.0(NP)   0.3–2.6   0.8(NP)   0.2–2.4   0.8(NP)   0.1–2.0   1.1
 P3   2.2–8.4   4.3(NP)   0.6–6.0   3.3   1.2–5.3   3.3   1.4–6.4   2.8(NP)   1.0–6.5   2.2(NP)   1.3–5.2   2.6(NP)
 Polone   0.0–0.7   0.2(NP)   0.0–0.3   0.2(NP)   0.0–0.3   0.2(NP)   0.0–0.3   0.1(NP)   0.0–0.3   0.1(NP)   0.0–0.3   0.1(NP)
Aldosterone 
 THA   0.1–1.1   0.6   0.1–1.1   0.4(NP)   0.1–0.8   0.4   0.1–0.9   0.5   0.0–1.1   0.4(NP)   0.1–0.9   0.5
 THB   0.3–1.4   0.6(NP)   0.1–1.1   0.5   0.2–1.1   0.5(NP)   0.2–1.3   0.5(NP)   0.1–1.7   0.56(NP)   0.2–1.3   0.7
 aTHB   0.3–3.3   1.8   0.1–3.4   1.7   0.3–2.7   1.5   0.6–3.2   1.3(NP)   0.3–3.4   1.0(NP)   0.1–3.0   1.6
Intermediate 
 THS   0.0–0.6   0.2(NP)   0.0–0.4   0.2(NP)   0.0–0.3   0.2   0.0–0.5   0.2   0.1–0.7   0.3(NP)   0.1–0.7   0.3(NP)
 PDL   0.4–2.4   0.9(NP)   0.3–2.0   0.8(NP)   0.4–1.8   0.8(NP)   0.2–2.0   0.9(NP)   0.3–1.9   0.7(NP)   0.2–1.6   0.9
 PTL   <0.1   <0.1   <0.1   <0.1   0.0–0.2   0.05(NP)   0.0–0.2   0.06(NP)   0.0–0.4   0.06(NP)   0.0–0.2   0.07(NP)
 aPDL   0.0–0.4   0.2(NP)   0.0–0.3   0.1(NP)   0.0–0.3   0.1(NP)   0.0–0.3   0.1(NP)   0.0–0.2   0.1(NP)   0.0–0.2   0.1(NP)
 TH-DOC   ≤0.1   <0.1   <0.1   <0.1   <0.1   <0.1   <0.1   <0.1   ≤0.1   <0.1   <0.1   <0.1
Fetal
 A’3   1.0–9.6   2.5(NP)   0.5–9.9   2.2(NP)   0.5–5.1   2.1(NP)   0.5–4.4   1.4(NP)   0.1–3.0   1.3   0.5–3.4   1.2(NP)
 16K-A’2   0.2–1.5   0.5(NP)   0.1–1.5   0.4(NP)   0.0–0.7   0.3   0.0–0.8   0.3(NP)   0.0–0.8   0.2(NP)   0.0–0.8   0.3(NP)
 16-OH-DHEA   1.2–11.3   4.2(NP)   0.2–12.6   2.0(NP)   0.4–3.4   1.9   0.1–4.2   1.2(NP)   0.1–3.2   0.7(NP)   0.2–4.6   1.0(NP)
 16,18-(OH)2-DHEA  <0.1   <0.1   <0.1   <0.1   <0.1   <0.1   <0.1   <0.1   <0.1   <0.1   <0.1   <0.1
 16-OH-p’ol   0.0–0.4   0.2   0.0–0.4   0.1(NP)   0.0–0.2   0.1(NP)   0.0–0.2   0.1(NP)   <0.1   <0.1   0.0–0.2   <0.1
 15-OH-PDL   <0.1   <0.1   <0.1   <0.1   <0.1   <0.1   <0.1   <0.1   <0.1   <0.1   <0.1   <0.1
 17-P3   0.1–4.0   2.0   0.2–3.9   1.1(NP)   0.2–2.3   1.2   0.1–1.7   0.8   0.1–1.3   0.5(NP)   0.1–1.5   0.8
 15-OH-P’DL   <0.1   <0.1   <0.1   <0.1   <0.1   <0.1   <0.1   <0.1   <0.1   <0.1   <0.1   <0.1
aData are presented as mean for parametric data or median for non-parametric (NP) data. Abbreviations as in Figure 1 and Supplemental 
Table 1.
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reference intervals we also calculated age and sex specific 
reference intervals for diagnostic ratios, as presented in 
Supplementary Table 4.
There were significant differences between dis-
tributions of metabolite excretions for women with or 
without the use of OCP (Table 4 and Figure 4). Women 
using OCP had lower excretions of androgen metabolites 
in the 20–29 year old age group (16.3 [10.6–19.8] vs. 21.8 
[13.9–23.9] µmol/24  h, p = 0.042). Progesterone metabo-
lite excretion was decreased in both age groups using 
OCP compared to corresponding age groups not using 
OCP (20–29 years: 1.9 [1.5–3.3] vs. 3.6 [2.5–7.6] µmol/24 h, 
p = 0.006 and 30–39  years: 2.6 [1.5–4.0] vs. 6.3 [3.4–13.2] 
µmol/24  h, p = 0.001). Multiple cortisol metabolites were 
excreted in significantly lower amounts in the women 
using OCP (Table 4). Total cortisol metabolite excretion 
showed a trend toward lower excretion in women using 
OCP in both age groups (20–29 years: 13.1 [10.6–21.4] vs. 
20.0 [12.4–31.2] µmol/24 h, p = 0.058 and 30–39 years: 15.8 
[11.1–22.5] µmol/24 h, p = 0.055, Figure 4).
Discussion
To the best of our knowledge, we here describe for the first 
time age- and sex-specific reference intervals for urinary 
steroid metabolite excretion in a well-defined and large 
healthy adult population with a broad age range. These 
urinary steroid profiles were determined with a newly-
developed and validated GC-MS/MS assay.
Well-defined reference intervals for the adult popu-
lation are essential, as USP in adult subjects has proven 
to be a valuable diagnostic tool in several clinical situa-
tions. For example, congenital adrenal hyperplasia (CAH), 
in particular the milder variants, might be diagnosed for 
the first time in adulthood [6, 7] by noticing moderately 
elevated P3, PTL and PDL excretions and/or elevated 
diagnostic ratios for these enzyme deficiencies (Sup-
plementary Table 4). In addition, USP can be helpful to 
evaluate the efficacy of glucocorticoid treatment in adult 
patients with CAH or for the diagnosis of licorice induced 
hypertension, which is reflected by an impaired hydroxy-
steroiddehydrogenase activity [8]. Patients with ACC often 
demonstrate several disorders in steroid biosynthesis. 
Retrospective data demonstrate the diagnostic potential 
of USP to differentiate between a benign adenoma and 
ACC [10, 11]. These abnormalities in steroid biosynthesis 
are clinically useful for both diagnosis as well as for the 
follow-up of patients with ACC [9].
Our data show that excretions of almost all 33 ana-
lyzed steroid metabolites are affected by age and gender, 
underscoring the need for age and sex specific reference 
intervals (Tables 3 and 4). In addition, it was demon-
strated that use of OCP resulted in a significantly lower 
urinary excretion of progesterone and androgen metabo-
lites. The decrease in progesterone and androgen excre-
tion can be explained by an OCP induced inhibition of 
the hypothalamic-pituitary-gonadal axis. In addition, 


































Figure 2: Median sum scores of urinary steroid metabolite excretion 
































Figure 3: Median sum scores of urinary steroid metabolite excretion 












































20–29 years + OCP





Figure 4: Urinary metabolite excretion in women with versus 
without use of OCP.
Boxes represent median with interquartile range. Whiskers repre-
sent minimum and maximum values. OCP, oral contraceptive pills. 
*p < 0.05 compared to the same age group using OCP.
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excretion in women on OCP, which is likely to result from 
an OCP induced elevation of the plasma cortisol-binding 
globulin (CBG) concentration [20, 21].
Our data are in agreement with previous reports 
showing a decline in androgen production with age, while 
cortisol production remains relatively stable through-
out adult life (Figures 2 and 3) [16, 22, 23]. The observed 
increase in cortisol metabolite excretion among women 
aged 70–79 years might be due to a decline of CBG levels 
or differences in body composition [24]. In addition, a sur-
vivor effect cannot be excluded. The decrease in proges-
terone metabolite excretion in women older than 50 years 
of age most likely reflects their postmenopausal status. 
Importantly, reference intervals for the diagnostic ratios 
of disorders in steroid biosynthesis are also significantly 
affected by age and sex (Supplementary Table 4). Calcu-
lation of these diagnostic ratios is very helpful in clini-
cal practice for the detection of various inborn errors of 
steroid biosynthesis and the follow-up of these conditions 
throughout adulthood [4, 6, 14]. Reference intervals for 
urinary steroid metabolites have been reported in several 
previous studies [4, 6, 11, 13–17]. We believe our study 
design is the most optimal one currently available. Pre-
vious published reference intervals did not take the age 
dependency of metabolite excretion into account as dem-
onstrated in the current study. It is therefore reasonable 
that our reference intervals differ slightly compared to 
studies in which the population was analyzed as a whole 
irrespective of age. Obviously, the latter approach results 
in regression to the mean. Also, analytically we optimized 
the setting by applying isotope labeled internal standards 
as much as possible, using the most specific technique 
currently available. Moreover, the strength of our study is 
the selection of a large healthy population. Consequently, 
we believe that our reference intervals are useful in an 
adult population for anyone using a similar GC-MS/MS (or 
GC-MS) method to ours.
The here described newly-developed GC-MS/MS assay 
has several advantages over our previous GC-MS method. 
First of all, GC-MS/MS methods have higher specificity 
than GC-MS methods. Tandem mass spectrometry has the 
ability to select one mass-to-charge ratio (m/z) ion and 
create specific fragmented ions out of this precursor ion 
in the second mass spectrometer. Consequently, interfer-
ence by other analytes with the same precursor m/z, but 
different product ions, is avoided. In addition, the GC-MS/
MS equipment provides an improved baseline separa-
tion, which enables automatic peak integration and 
reduces time of analysis [25]. Pre-set requirements (based 
on ISO15189 and Dutch guidelines for validation of ana-
lytical methods) for precision, linearity, recovery, LLOQ, 
carry-over and stability were met for all steroid metabo-
lites and results were improved compared to the former 
GC-MS method. Only for 16-KA’2 the inter- and intra-
assay CVs were noted to be relatively high. This particu-
lar steroid metabolite, however, is of limited diagnostic 
value. Another advantage of the GC-MS/MS is the reduc-
tion of analysis time with 1 day. In addition, the integrated 
software provides automatic chromatographic data inte-
gration, whereby obtained results are transferred to the 
laboratory information system, which in turn generates 
user-friendly graphical data reports.
For more than a decade we and 27 other laboratories 
from all over the world participate in an external steroid 
profile quality assessment scheme organized by the Uni-
versity College London Hospitals (London, UK) and the 
Stichting Kwaliteitsbewaking Medische Laboratorium-
diagnostiek (SKML, The Netherlands). Since a standard 
reference method is lacking, participation guarantees 
quality and is the best way of demonstrating accuracy. 
In this quality scheme our GC-MS/MS method performs 
better than average and scores in the top 7 (range 1–7) of 28 
laboratories in the year 2016 with a constant MOM score 
of 2 or higher.
Although liquid chromatography-tandem mass 
spectrometry (LC/MS-MS) is expected to become the high-
throughput method of choice for targeted limited steroid 
determinations, we agree with other authors [4] that USP 
by GC-MS will remain the most powerful discovery tool 
for defining disorders of steroid biosynthesis for years 
to come. Advantages of applying USP instead of targeted 
blood measurements of adrenal steroids are the elimina-
tion of diurnal variation by using 24  h urine collections 
and the generation of a so-called metabolome including 
characterization of unknown metabolites. LC-MS/MS is 
not capable of profiling >20–30  metabolites simultane-
ously, although a method for glucocorticoid metabolites 
has been described [26]. For such profiling chromatogra-
phy with high plate numbers remains very important and 
therefore GC-MS is still the superior technique. A future 
development could be the use of a multidimensional sta-
tistical approach of data interpretation (metabolomics). 
Data from the current study might be very useful for the 
development of such a tool.
In conclusion, we developed a new GC-MS/MS method 
for USP which is suitable for high-throughput analysis. 
Widely applicable age and sex specific reference intervals 
for 33  metabolites and their diagnostic ratios have been 
defined for male and female individuals aged 20–79 years. 
In addition, we have shown that the use of OCP influences 
USP in women 20–39 years of age, which should be taken 
into account when interpreting these results.
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